STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

JERSEY CITY, N.J., March 12, 2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

STEQEYMA ®, one of the first-wave biosimilars to STELARA ®, is now available in the U.S. Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

Otulfi, the fourth Fresenius biosimilar available in the U.S., is available in vial and prefilled syringe presentations. (Photo: Business Wire) The Fresenius ustekinumab biosimilar, Otulfi ® was ...

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union 03.03.2025 / 14:00 CET/CEST The issuer is solely responsible for the content of ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ...

Planegg-Martinsried, Germany - Formycon AG FYB "Formycon") and its commercialization partner Fresenius announce the commercial availability of Otulfi ® 1, a biosimilar to Stelara ®2 in the ...